Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OLN102
- Development stage
- Preclinical
- Lead developer
- Ollin Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
OLN102 (also known as VBS-102) is a first-in-class bispecific monoclonal antibody targeting both the Thyroid-Stimulating Hormone Receptor (TSHR) and the Insulin-like Growth Factor 1 Receptor (IGF-1R). It is being developed by Ollin Biosciences in collaboration with VelaVigo for the treatment of thyroid eye disease (TED) and the underlying autoimmune condition of Graves' disease. Unlike existing therapies like teprotumumab (Tepezza) which only inhibit IGF-1R, OLN102 simultaneously blocks both IGF-1R and TSHR, potentially offering synergistic efficacy, improved safety, and more precise tissue targeting. The drug is designed for subcutaneous administration and is expected to enter clinical development in 2026.
- Other names
- VBS-102VBS102VBS 102
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on OLN102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OLN102.